Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single and Repeat Dosing Study of the Safety, Drug Exposure and Clinical Activity of R-2487 in Patients With Rheumatoid Arthritis

Next Previous
Trial Profile

A Single and Repeat Dosing Study of the Safety, Drug Exposure and Clinical Activity of R-2487 in Patients With Rheumatoid Arthritis

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs R 2487 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Rise Therapeutics

Most Recent Events

  • 02 Jun 2026 According to Rise Therapeutics media release, The Company's independent Data Monitoring Committee (DMC) recently completed a scheduled review of available safety and clinical data from the study and recommended progression of clinical development. This recommendation marks an important advancement for the R-2487 clinical program and enables continued evaluation of the therapy over an extended treatment period.
  • 02 Jun 2026 According to Rise Therapeutics media release, Data from the 4-week dose expansion cohort will be presented at upcoming national and international rheumatology and immunology conferences, as appropriate and as analyses become available.
  • 02 Jun 2026 According to Rise Therapeutics media release, company announced the completion of full enrollment in the 4-week dose expansion cohort of its Phase 1b clinical trial (NCT05961592).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top